Designing chimeric antigen receptors to effectively and safely target tumors.
Designing chimeric antigen receptors to effectively and safely target tumors.
复制标题
DOI：
10.1016/j.coi.2015.01.002
复制
发表时间：
2015-04
影响因子：
7
通讯作者：
Riddell, Stanley R.
中科院分区：
文献类型：
--
作者：
Jensen, Michael C.;Riddell, Stanley R.
过继性转移T细胞工程化以表达靶向肿瘤细胞表面分子的人工嵌合抗原受体（汽车）已经成为癌症免疫治疗的令人兴奋的新方法。在用CD 19特异性CAR修饰的T细胞（CAR-T）治疗的晚期B细胞恶性肿瘤患者中进行的临床试验显示出令人印象深刻的抗肿瘤疗效，从而乐观地认为这种方法将用于治疗常见的实体瘤。由于CAR-T细胞识别肿瘤细胞不依赖于其人类白细胞抗原（HLA）分子的表达，因此可以消除通过下调HLA和/或突变抗原加工机制的组分而逃避常规T细胞的肿瘤。在T细胞中引入或缺失额外基因的能力具有提供具有新属性的治疗性细胞产物的潜力，所述新属性克服免疫抑制性肿瘤微环境中免疫介导的肿瘤消除的障碍。本文将讨论最近的概念，在开发有效和安全的合成汽车过继性T细胞治疗（ACT）。
The adoptive transfer of T cells engineered to express artificial chimeric antigen receptors (CARs) that target a tumor cell surface molecule has emerged as an exciting new approach for cancer immunotherapy. Clinical trials in patients with advanced B cell malignancies treated with CD19-specific CAR-modified T cells (CAR-T) have shown impressive antitumor efficacy, leading to optimism that this approach will be useful for treating common solid tumors. Because CAR-T cells recognize tumor cells independent of their expression of human leukocyte antigen (HLA) molecules, tumors that escape conventional T cells by downregulating HLA and/or mutating components of the antigen processing machinery can be eliminated. The ability to introduce or delete additional genes in T cells has the potential to provide therapeutic cell products with novel attributes that overcome impediments to immune mediated tumor elimination in immunosuppressive tumor microenvironments. This review will discuss recent concepts in the development of effective and safe synthetic CARs for adoptive T cell therapy (ACT).
登录
查看更多内容
影响因子：
10.1
作者：
Hudecek M;Sommermeyer D;Kosasih PL;Silva-Benedict A;Liu L;Rader C;Jensen MC;Riddell SR
通讯作者：
Riddell SR
影响因子：
17.1
作者：
Fedorov VD;Themeli M;Sadelain M
通讯作者：
Sadelain M
DOI：
10.1158/1078-0432.ccr-11-0503
发表时间：
2011-08-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Klebanoff CA;Gattinoni L;Palmer DC;Muranski P;Ji Y;Hinrichs CS;Borman ZA;Kerkar SP;Scott CD;Finkelstein SE;Rosenberg SA;Restifo NP
通讯作者：
Restifo NP
影响因子：
82.9
作者：
Gattinoni L;Lugli E;Ji Y;Pos Z;Paulos CM;Quigley MF;Almeida JR;Gostick E;Yu Z;Carpenito C;Wang E;Douek DC;Price DA;June CH;Marincola FM;Roederer M;Restifo NP
通讯作者：
Restifo NP
DOI：
10.1073/pnas.0503726102
发表时间：
2005-07-05
影响因子：
11.1
作者：
Klebanoff, CA;Gattinoni, L;Restifo, NP
通讯作者：
Restifo, NP